BioPharmSignal logoBioPharmSignal

Biotech News

Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (NKTR)Nektar TherapeuticsEarnings

SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 7, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to

Related news

NKTRNektar Therapeutics2026-07-28 22:00 EST

Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

NKTRNektar Therapeutics2026-08-13 20:15 EST

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

IMVTImmunovant2026-07-23 20:05 EST

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

IMVTImmunovant2026-08-06 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

RVMDRevolution Medicines2026-07-29 20:05 EST

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

GERNGeron2026-07-22 11:00 EST

Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

View all latest news

Nektar Therapeutics

Immune-Regulatory Therapeutics Nektar Therapeutics develops biologic medicines that selectively modulate immune-cell pathways. Its current portfolio emphasizes regulatory T-cell biology for autoimmune and inflammatory diseases. Rezpegaldesleukin Rezpegaldesleukin is an IL-2 pathway agonist designed to expand and activate regulatory T...

Recent company news

NKTRNektar Therapeutics2026-08-13 20:15 EST

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

NKTRNektar Therapeutics2026-07-28 22:00 EST

Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

NKTRNektar Therapeutics2026-07-24 20:15 EST

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NKTRNektar Therapeutics2026-07-21 11:00 EST

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

NKTRNektar Therapeutics2026-06-26 20:30 EST

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
74.02 USD
Market cap
1.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States